Pfizer's $2bn+ obesity bet, and other weight-loss news Pfizer licenses another GLP-1 agonist from YaoPharma, plus clinical updates from Zealand, Structure, Ascletis, Wave, and Boehringer Ingelheim.

#Pfizer #obesity #weightloss #FosunPharma #YaoPharma #GLP1agonist #oralGIPanalogue #Metsera #EliLilly #NovoNordisk #Wegovy #ZealandPharma #metabolicdiseases #Roche #BoehringerIngelheim #GLP1glucagonagonist #StructureTherapeutics #AscletisPharma #WaveLifeSciences #Gubra
zurl.co/AwsrK

Pfizer's $2bn+ obesity bet, and other weight-loss news Pfizer licenses another GLP-1 agonist from YaoPharma, plus clinical updates from Zealand, Structure, Ascletis, Wave, and Boehringer Ingelheim.

It has been a busy week for news in the superheated #obesity category, headlined by news that #Pfizer has #licensed a therapy from a subsidiary of China's #FosunPharma, in a deal that includes $150 million in upfront payments.

pharmaphorum.com/news/pfizers...

Teva and Fosun Pharma partner on early-stage oncology drug - PharmaTimes The candidate is being evaluated as both a monotherapy and in combination pembrolizumab

#drugdevelopment #Oncology #FosunPharma #TEV56278 #Teva #monotherapy #combinationtherapy #pembrolizumab #clinicaldatageneration #antiPD1IL2ATTENUKINEtherapy #antitumourTcellactivity #MerckandCo #MSD #enhancedTcellinfiltration #immunememory #preclinicalstudies
pharmatimes.com/news/teva-an...